Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
The manuscript, authored by LineaRx, the Companys majority-owned biotherapeutics subsidiary, and LineaRxs development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.
- The manuscript, authored by LineaRx, the Companys majority-owned biotherapeutics subsidiary, and LineaRxs development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.
- It details positive data showing safety and immunogenicity of a linDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned cats.
- Separately, LineaRx announced the successful expression in vitro of its linDNA SARS-CoV-2 vaccine candidate encapsulated within lipid nanoparticles (LNP).
- Evvivax pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on proprietary viral vectors and DNA platform technologies.